Third Rock-Backed Abata Secures $95M for T-reg Cell Therapy Against MS

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Clasp, Backed by Catalio, Third Rock & Novo, Gets $150M for Specific T-cell Engagers
Investing in the Future of Medicine: Reid Huber on The Long Run
Septerna, Backed by Third Rock and RA, Gets $150M for GPCR Drug Discovery
Third Rock, Arch, J&J Pump $100M into Rapport to Develop Precision Neuro Drugs